Thyroid Hormone Action

甲状腺激素作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): The long-term objective of this project is to understand the molecular mechanisms of thyroid hormone action. Thyroid hormone is an important regulator of development and homeostasis, and abnormalities in thyroid status correlate with many human diseases ranging from cancer to birth defects to metabolic disorders. Thyroxine (T4) is the major form of thyroid hormone that is secreted from the thyroid gland, and T4 is metabolized to the active hormone T3 by enzymatic deiodination. T3 regulates the transcription of thyroid hormone responsive genes by binding to and activating nuclear thyroid hormone receptors. However, there are many effects of thyroid hormone that occur much faster than the timescale of transcriptional regulation, and the molecular mechanisms of these rapid effects are unknown. This research plan is constructed around the hypothesis that rapid thyroid hormone signaling involves a novel metabolite of T4 that is chemically distinct from T3. This hypothesis is supported by experiments showing the existence of this novel metabolite in tissue, as well as the induction of rapid physiological responses when the metabolite is administered in vivo. In addition, this T4 metabolite is a potent agonist of a newly discovered orphan G protein-coupled receptor (GPCR) related to the family of a biogenic amine GPCRs. This research plan seeks to further explore this novel pathway of thyroid hormone signaling. Specific aim 1 involves chemical modification of the metabolite to delineate the structural features important to GPCR activation. Specific aim 2 is a study to understand the enzymology responsible for generating the rapid-acting T4 metabolite. Specific aim 3 involves the isolation, expression, and pharmacological characterization of the different subtypes of the GPCR that responds to the metabolite. Specific aim 4 is an approach to examine different tissues for the presence of the metabolite and perform quantitative analysis. Specific aim 5 is a plan to develop a chemical antagonist of the metabolite that will be useful for studying the in vivo biology of this new thyroid hormone signaling pathway.
描述(由申请人提供):本项目的长期目标是了解甲状腺激素作用的分子机制。甲状腺激素是发育和体内平衡的重要调节剂,甲状腺状态的异常与许多人类疾病相关,从癌症到出生缺陷到代谢紊乱。甲状腺素(T4)是甲状腺分泌的甲状腺激素的主要形式,T4通过酶促脱碘代谢为活性激素T3。T3通过结合并激活核甲状腺激素受体来调节甲状腺激素应答基因的转录。然而,甲状腺激素的许多作用比转录调节的时间尺度快得多,这些快速作用的分子机制尚不清楚。这项研究计划是围绕一个假设,即快速甲状腺激素信号涉及一种新的T4代谢产物,其化学性质与T3不同。该假设得到了实验的支持,这些实验显示组织中存在这种新型代谢物,以及当体内给予代谢物时诱导快速生理反应。此外,这种T4代谢物是一种新发现的孤儿G蛋白偶联受体(GPCR)的强效激动剂,该受体与生物胺GPCR家族相关。这项研究计划旨在进一步探索这种甲状腺激素信号传导的新途径。具体目标1涉及代谢物的化学修饰,以描述对GPCR活化重要的结构特征。具体目标2是一项研究,以了解负责产生速效T4代谢产物的酶学。具体目标3涉及对代谢物有反应的GPCR不同亚型的分离、表达和药理学表征。具体目标4是检查不同组织中代谢物的存在并进行定量分析的方法。具体目标5是开发代谢物的化学拮抗剂的计划,该化学拮抗剂将用于研究这种新的甲状腺激素信号传导途径的体内生物学。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS Sterling SCANLAN其他文献

THOMAS Sterling SCANLAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS Sterling SCANLAN', 18)}}的其他基金

Chemical Biology Studies of 3-Iodothyronamine and Related Thyroid Hormone Metabol
3-碘甲腺胺及相关甲状腺激素代谢的化学生物学研究
  • 批准号:
    8464697
  • 财政年份:
    2012
  • 资助金额:
    $ 31.19万
  • 项目类别:
Chemical Biology Studies of 3-Iodothyronamine and Related Thyroid Hormone Metabol
3-碘甲腺胺及相关甲状腺激素代谢的化学生物学研究
  • 批准号:
    8235583
  • 财政年份:
    2012
  • 资助金额:
    $ 31.19万
  • 项目类别:
Chemical Biology Studies of 3-Iodothyronamine and Related Thyroid Hormone Metabol
3-碘甲腺胺及相关甲状腺激素代谢的化学生物学研究
  • 批准号:
    8665414
  • 财政年份:
    2012
  • 资助金额:
    $ 31.19万
  • 项目类别:
STRUCTURE & MECHANISM OF HYDROLYTIC ANTIBODIES
结构
  • 批准号:
    7601805
  • 财政年份:
    2007
  • 资助金额:
    $ 31.19万
  • 项目类别:
STRUCTURE & MECHANISM OF HYDROLYTIC ANTIBODIES
结构
  • 批准号:
    7369025
  • 财政年份:
    2006
  • 资助金额:
    $ 31.19万
  • 项目类别:
STRUCTURE & MECHANISM OF HYDROLYTIC ANTIBODIES
结构
  • 批准号:
    7180908
  • 财政年份:
    2005
  • 资助金额:
    $ 31.19万
  • 项目类别:
STRUCTURE & MECHANISM OF HYDROLYTIC ANTIBODIES
结构
  • 批准号:
    6976595
  • 财政年份:
    2004
  • 资助金额:
    $ 31.19万
  • 项目类别:
CATALYTIC ANTIBODY DESIGN & CHARACTERIZATION
催化抗体设计
  • 批准号:
    6456785
  • 财政年份:
    2001
  • 资助金额:
    $ 31.19万
  • 项目类别:
LIGAND PHARMACOLOGY OF ESTROGEN RECEPTORS
雌激素受体的配体药理学
  • 批准号:
    6381790
  • 财政年份:
    2000
  • 资助金额:
    $ 31.19万
  • 项目类别:
LIGAND PHARMACOLOGY OF ESTROGEN RECEPTORS
雌激素受体的配体药理学
  • 批准号:
    6517731
  • 财政年份:
    2000
  • 资助金额:
    $ 31.19万
  • 项目类别:

相似海外基金

Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
  • 批准号:
    10412227
  • 财政年份:
    2022
  • 资助金额:
    $ 31.19万
  • 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
  • 批准号:
    10610473
  • 财政年份:
    2022
  • 资助金额:
    $ 31.19万
  • 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
  • 批准号:
    10799162
  • 财政年份:
    2022
  • 资助金额:
    $ 31.19万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6639179
  • 财政年份:
    2001
  • 资助金额:
    $ 31.19万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6724797
  • 财政年份:
    2001
  • 资助金额:
    $ 31.19万
  • 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
  • 批准号:
    6636512
  • 财政年份:
    2001
  • 资助金额:
    $ 31.19万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6266928
  • 财政年份:
    2001
  • 资助金额:
    $ 31.19万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6539099
  • 财政年份:
    2001
  • 资助金额:
    $ 31.19万
  • 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
  • 批准号:
    6326889
  • 财政年份:
    2001
  • 资助金额:
    $ 31.19万
  • 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
  • 批准号:
    6520329
  • 财政年份:
    2001
  • 资助金额:
    $ 31.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了